Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

LIF Protein (AA 23-202)

LIF Origine: Humain Hôte: Escherichia coli (E. coli) Recombinant > 95 % by SDS-PAGE analysis. Active
N° du produit ABIN2018195
  • Antigène Voir toutes LIF Protéines
    LIF (Leukemia Inhibitory Factor (LIF))
    Type de proteíne
    Recombinant
    Activité biologique
    Active
    Attributs du protein
    AA 23-202
    Origine
    • 22
    • 15
    • 4
    • 3
    • 2
    • 2
    • 1
    Humain
    Source
    • 21
    • 16
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    Escherichia coli (E. coli)
    Attributs du produit
    ED50 < 0.2 ng/mL, measured by a cell differentiation assay using TF-I cells, corresponding to a specific activity of > 5 x 10^6 units/mg.
    Pureté
    > 95 % by SDS-PAGE analysis.
    niveau d'endotoxine
    < 0.2 EU/μg, determined by LAL method.
    Top Product
    Discover our top product LIF Protéine
  • Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Reconstituted in ddH2O at 100 μg/mL.
    Buffer
    Lyophilized after extensive dialysis against PBS.
    Stock
    -80 °C
    Stockage commentaire
    Lyophilized recombinant human Leukemia Inhibitory Factor (rhLIF) remains stable up to 6 months at -80 °C from date of receipt. Upon reconstitution, rhLIF remains stable up to 2 weeks at 4 °C or up to 3 months at -20 °C. ,
    Date de péremption
    6 months
  • Huang, Li, Alonso-Gonzalez, Gorre, Keatley, Green, Turner, Kallingappa, Verma, Oback: "A virus-free poly-promoter vector induces pluripotency in quiescent bovine cells under chemically defined conditions of dual kinase inhibition." dans: PLoS ONE, Vol. 6, Issue 9, pp. e24501, (2011) (PubMed).

    Yu, Kastin, Pan: "TNF reduces LIF endocytosis despite increasing NFkappaB-mediated gp130 expression." dans: Journal of cellular physiology, Vol. 213, Issue 1, pp. 161-6, (2007) (PubMed).

  • Antigène
    LIF (Leukemia Inhibitory Factor (LIF))
    Abstract
    LIF Produits
    Sujet
    Leukemia Inhibitory Factor (LIF) is a pleiotropic cytokine belonging to the long four-helix bundle cytokine superfamily. LIF shares tertiary structure with several other cytokines, including Interleukin-6 (IL-6), Oncostatin M, ciliary neurotropic factor, and cardiotrophin-1, and their functions in vivo are also redundant to some extent. LIF can bind to the common receptor of IL-6 subfamily, gp130, and then recruit its own receptor LIF Receptor to form a ternary complex. The basal expression of LIF in vivo is low, and its expression is induced by pro-inflammatory factors, including lipopolysaccharide, IL-1, and IL-17, and inhibited by anti-inflammatory agents, including IL-4 and IL-13. The functions of LIF include proliferation of primordial germ cells, regulation in blastocyst implantation and early pregnancy, and maintenance of pluripotent embryonic stem cells.Recombinant human Leukemia Inhibitory Factor (rhLIF) produced in E. coli is a single non-glycosylated polypeptide chain containing 180 amino acids. A fully biologically active molecule, rhLIF has a molecular mass of 19.7 kDa analyzed by reducing SDS-PAGE.
    Synonyms: D factor, MLPLI
    Poids moléculaire
    19.7 kDa, observed by reducing SDS-PAGE.
    UniProt
    P15018
    Pathways
    Signalistation JAK/STAT, Positive Regulation of Peptide Hormone Secretion, Negative Regulation of Hormone Secretion, Stem Cell Maintenance, Growth Factor Binding
Vous êtes ici:
Support technique